These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2428463)

  • 1. Use of four monoclonal antibodies to detect tumor markers.
    Kawahara M; Terasaki PI; Chia D; Johnson C; Hermes M; Tokita K
    Cancer; 1986 Nov; 58(9):2008-12. PubMed ID: 2428463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of sialylated LewisX antigen in cancer sera using a sandwich radioimmunoassay.
    Kawahara M; Chia D; Terasaki PI; Roumanas A; Sugich L; Hermes M; Iguro T
    Int J Cancer; 1985 Oct; 36(4):421-5. PubMed ID: 2995258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
    Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
    Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
    Wu JT
    Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
    Wu JT; Miya T; Knight JA; Knight DP
    Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of measurement of a carbohydrate antigenic determinant 19-9 (CA 19-9) for monitoring colorectal cancer patients.
    Tomoda H; Furusawa M
    Jpn J Surg; 1986 Jan; 16(1):73-5. PubMed ID: 2421035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advantages and limitations of combined assays of 4 serum markers in various types of malignant neoplasms].
    Lanza E; Coda C; Ramella S; Ciambellotti E; Moro G; Cartia GL
    Minerva Med; 1986 Sep; 77(34-35):1521-5. PubMed ID: 3463886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEA-related antigens: molecular biology and clinical significance.
    Shively JE; Beatty JD
    Crit Rev Oncol Hematol; 1985; 2(4):355-99. PubMed ID: 3886178
    [No Abstract]   [Full Text] [Related]  

  • 9. [Ca 19-9 and Ca 50 in the diagnosis of bronchial carcinoma: comparison with CEA].
    Pecchio F; Rapellino M; Oliaro A; Moscato D; Adamo R; Albertino B; Lo Faso C; Faga C; Borasio P
    Minerva Med; 1988 Mar; 79(3):183-6. PubMed ID: 2834670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
    Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
    Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9.
    Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
    Eur J Surg Oncol; 1987 Jun; 13(3):197-201. PubMed ID: 3474158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
    Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
    Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum carbohydrate 19-9 Tm and bronchial cancer. Comparative study with another tumor marker, carcinoembryonic antigen].
    Bisset JP; Kleisbauer JP; Roux F; Treffot MJ
    Pathol Biol (Paris); 1985 Jun; 33(6):672-6. PubMed ID: 3900886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of tumor markers in cases of colorectal cancer: CEA and CA 19-9].
    Desaive C; Servais R; Collette J; Denis D; Reginster JY; Franchimont P
    Acta Gastroenterol Belg; 1987; 50(1):65-78. PubMed ID: 3480671
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.
    Kuusela P; Jalanko H; Roberts P; Sipponen P; Mecklin JP; Pitkänen R; Mäkelä O
    Br J Cancer; 1984 Feb; 49(2):135-9. PubMed ID: 6582896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
    Szymendera JJ
    Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
    Bast RC; Klug TL; Schaetzl E; Lavin P; Niloff JM; Greber TF; Zurawski VR; Knapp RC
    Am J Obstet Gynecol; 1984 Jul; 149(5):553-9. PubMed ID: 6204531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
    Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
    Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H; Teshima K; Noda K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.